Dupilumab, an anti-IL-4Rα monoclonal antibody, inhibits IL-4/IL-13 signaling, key drivers of type 2/Th2 immune diseases (e.g. atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting β2-agonists.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2DmEDFG
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objectives Adult sagittal posture is established during childhood and adolescence. A flattened or hypercurved spine is associated with poore...
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
CBN News Cancer Took Most of His Tongue, but This Pastor Is Still Singing ... CBN News A youth pastor in San Diego, California is not ...
-
Family: Know the drill New Straits Times Online One of my sons had this so often that his tonsils were removed. ... However, for som...
-
The E3 ubiquitin ligase F-box and WD repeat domain containing 7 (FBW7α) functions as a putative tumor suppressor in non-small cell lung canc...
-
In this study, the changes in pH, organic acid content, acidity, and salinity of kimchi prepared at 0 days, stored 1–8 weeks at 4 and 10°C, ...
-
When you make pizza this good you are allowed to brag about it. Come try a square of the best pizza in Erie. Ohhh yeah, we have ice cream no...
-
The March for Science reflects the growing gap between slow, steady, vital scientific gains and quick-fire, opportunist US politics, says D...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου